LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BD Diagnostics Collaborate With Bruker to Improve Microbial Identification

By LabMedica International staff writers
Posted on 11 Oct 2010
Print article
BD Diagnostics (Sparks, MD, USA) announced an international codevelopment and comarketing collaboration with Bruker Daltonics Inc. (Billerica, MA, USA).

BD Diagnostics is a segment of the Becton, Dickinson and Company (Franklin Lakes, NJ, USA), and Bruker Daltonics is a subsidiary of Bruker Corporation (Billerica, MA, USA). The collaboration will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing.

Through this collaboration, identification of microorganisms will be performed with the Bruker MALDI Biotyper, a mass spectrometry-based proteomic "fingerprinting” system specifically configured for rapid identification of bacteria and fungi. BD and Bruker intend to combine the MALDI Biotyper microbial ID system with automated antimicrobial susceptibility testing on the BD Phoenix Microbiology System. The MALDI Biotyper and BD EpiCenter software integration will be further developed to optimize workflows for rapid MALDI Biotyper pathogen identification directly on positive blood cultures from the leading BD BACTEC blood culture system. This rapid blood culture-to-ID workflow is supported by Bruker's new MALDI Sepsitype consumables kit.

Microbial identification and antimicrobial susceptibility testing is the end-point of the major work a microbiology laboratory performs on a daily basis. After culturing and isolating bacteria and fungi from patient specimens, organisms need to be identified and tested to determine which drugs will inhibit or stop their growth. The Bruker MALDI Biotyper allows highly accurate, rapid, and cost-effective identification through a process in which organisms are identified by the unique spectrum of the major proteins and peptides that constitute their makeup.

Frank Laukien, Ph.D., President and CEO of Bruker Corporation, said, "Working with a worldwide leader in microbiology and infectious disease will enable us to further expand the groundbreaking MALDI Biotyper molecular method for microbial identification to its full extent.”

Related Links:

BD Diagnostics
Bruker Daltonics Inc.
Becton, Dickinson and Company
Bruker Corporation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more